Search results
The Hunt for Virus Treatments Continues Post Covid-19
Digital Journal· 7 days ago(NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. The threat of viruses is back in the ...
Why Moderna Stock Is a No-Brainer Buy Right Now | The Motley Fool
The Motley Fool· 4 days agoIn 2022, the biotech company generated sales of nearly $18.9 billion, but it expects revenue of only...
Why Moderna Stock Is a No-Brainer Buy Right Now
The Motley Fool via AOL· 4 days agoCMV is the top infectious cause of birth defects in the U.S. and currently has no approved vaccines. With Merck, Moderna is testing a combination of Merck's Keytruda with ...
Moderna director Noubar Afeyan sells over $2.2m in company stock By Investing.com
Investing.com· 6 days agoModerna , Inc. (NASDAQ:MRNA) Director Noubar Afeyan has recently sold a substantial number of shares...
